Last reviewed · How we verify
Choline Alfoscerate 400mg
Choline Alfoscerate 400mg, marketed by Daewoong Bio Inc., is a drug with a key composition patent expiring in 2028. The drug's primary strength lies in its current market presence, leveraging its established mechanism of action. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | Choline Alfoscerate 400mg |
|---|---|
| Sponsor | Daewoong Bio Inc. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of ChOline ALfoscerate in Patient With Mild to Moderate Alzheimer's Disease (PHASE4)
- Clinical Effectiveness of Choline Alphoscerate for Older Adults With Major Depression and Subjective Memory Complaints (NA)
- A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment (PHASE4)
- A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate in Vascular Cognitive Impairment Patients (PHASE4)
- Effect of Choline Alphoscerate on Cognitive Function in Alzheimer's Dementia (PHASE4)
- The Effect of Choline Alfoscerate on Improvement of Cognitive Function in Elderly Patients With Diabetes (PHASE3)
- To Evaluate Safety and the Pharmacokinetic Characteristics After Oral Administration of HT-003 Compared With Choline Alfoscerate Capsule in Healthy Adult Male Volunteers (PHASE1)
- The Efficacy of Gliatiline® on Post-stroke Patients With Vascular Cognitive Impairment no Dementia (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Choline Alfoscerate 400mg CI brief — competitive landscape report
- Choline Alfoscerate 400mg updates RSS · CI watch RSS
- Daewoong Bio Inc. portfolio CI